Riboflavin ophthalmic Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Mar 14, 2022.
Riboflavin ophthalmic is also known as: Photrexa, Photrexa Viscous
Riboflavin ophthalmic Pregnancy Warnings
Animal development and reproductive studies have not been conducted. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
Use should be avoided.
US FDA pregnancy category: Not formally assigned to a pregnancy category.
Risk Summary: There are no data available on use of this drug in pregnant women to inform of a drug-related risk.
Riboflavin ophthalmic Breastfeeding Warnings
Benefit should clearly outweigh risk.
Excreted into human milk: Data not available
Excreted into animal milk: Unknown
Comment: The effects in the nursing infant are unknown.
There are no data regarding the presence of this drug in human milk or its effect on milk production.
See also
References for pregnancy information
- "Product Information. Photrexa (riboflavin ophthalmic)." Avedro, Inc. (2016):
- "Product Information. Photrexa Viscous (riboflavin ophthalmic)." Avedro, Inc. (2016):
References for breastfeeding information
- "Product Information. Photrexa (riboflavin ophthalmic)." Avedro, Inc. (2016):
- "Product Information. Photrexa Viscous (riboflavin ophthalmic)." Avedro, Inc. (2016):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
